New Delhi, Apr 15 (PTI) Biocon Biologics on Tuesday said it has inked a settlement and licensing pact with Regeneron, paving the way to commercialise its biosimilar product Yesafili in the US.

Yesafili, a vascular endothelial growth factor (VEGF) inhibitor used to treat several types of ophthalmology conditions, is a biosimilar of its reference product Eylea (aflibercept).

Also Read | Kolkata Fatafat Result Today: Kolkata FF Result for April 15, 2025 Declared, Check Winning Numbers and Result Chart of Satta Matka-Type Lottery Game.

Biocon Biologics and Regeneron executed the settlement agreement to dismiss the pending appeal at the US Court of Appeals for the Federal Circuit (USCAFC) and the pending litigation at the US District Court for the Northern District of West Virginia, Clarksburg Division, Biocon Biologics said in a statement.

The agreement enables the company, a unit of Biocon Ltd, to launch its product in the US in the second half of 2026 or earlier in certain circumstances, it added.

Also Read | Shillong Teer Results Today, April 15 2025: Winning Numbers, Result Chart for Shillong Morning Teer, Shillong Night Teer, Khanapara Teer, Juwai Teer and Jowai Ladrymbai.

The terms of the settlement are confidential, it stated.

"This settlement clears the path for Biocon Biologics to be among the first to bring a reliable, high-quality aflibercept biosimilar to patients and healthcare providers in the US," Biocon Biologics CEO & Managing Director Shreehas Tambe said.

As the first-to-file interchangeable biosimilar to Eylea, Yesafili affirms company's scientific strength and marks strategic entry into ophthalmology, expanding footprint in the US, he added.

The US Food and Drug Administration (USFDA) had approved Yesafili (aflibercept-jbvf), an interchangeable biosimilar aflibercept, in May 2024.

Additionally, Biocon Biologics reached a settlement agreement in Canada with Bayer Inc and Regeneron Pharmaceuticals, Inc. for the launch of Yesafili no later than July 1, 2025.

The product is intended for the treatment of neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion, visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation.

Biocon shares were trading 3.29 per cent up at Rs 326.95 apiece on BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)